You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mayzent

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Assessment of Pregnancy Outcomes in Patients Treated With

Recruiting
  • Multiple Sclerosis
  • Siponimod
  • La Jolla, California
    Novartis Investigative Site
Jan 20, 2023

Mayzent Onboarding of Secondary Progressive Multiple Sclerosis

Completed
  • Secondary Progressive Multiple Sclerosis
    • Camperdown, New South Wales, Australia
    • +1 more
    Apr 19, 2023

    Secondary-progressive Multiple Sclerosis Trial in Buffalo (Mayzent, Ocrevus)

    Recruiting
    • Secondary-progressive Multiple Sclerosis
    • Buffalo, New York
      University at Buffalo, Buffalo General Hospital
    Oct 10, 2022

    Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

    Recruiting
    • Active Secondary Progressive Multiple Sclerosis
    • siponimod
    • Ancona, AN, Italy
    • +19 more
    Dec 27, 2022

    Mayzent on SPMS Patients in a Long-term Non-interventional Study

    Recruiting
    • Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
    • Siponimod
    • Baden, Aargau, Switzerland
    • +8 more
    May 16, 2022

    Multiple Sclerosis Trial (Siponimod)

    Available
    • Multiple Sclerosis
    • (no location specified)
    Sep 13, 2022

    Among Healthcare Professionals and MS Patients to Assess Their

    Recruiting
    • Multiple Sclerosis
      • Basel, Switzerland
        Novartis Investigative Site
      Mar 21, 2022

      Secondary Progressive Multiple Sclerosis Trial in Germany (BAF312, Baseline disease modifying therapies (DMTs))

      Active, not recruiting
      • Secondary Progressive Multiple Sclerosis
      • BAF312
      • Baseline disease modifying therapies (DMTs)
      • Mittweida, Sachsen, Germany
      • +9 more
      Aug 9, 2022

      results Surveillance for Mayzent in SPMS Patients

      Recruiting
      • Secondary Progressive Multiple Sclerosis (SPMS)
      • Mayzent
      • Anjo, Aichi, Japan
      • +210 more
      Dec 22, 2022

      Multiple Sclerosis, Relapsing-Remitting Trial in United Kingdom, United States (Early Highly Effective Therapies Group,

      Recruiting
      • Multiple Sclerosis, Relapsing-Remitting
      • Early Highly Effective Therapies Group
      • Escalation Therapies Group
      • Aurora, Colorado
      • +30 more
      Jul 22, 2022

      COVID-19 Vaccine Response in Treated MS Patients

      Recruiting
      • Multiple Sclerosis
      • Healthy
      • Blood draw
      • Boston, Massachusetts
        Brigham MS Center
      Jul 26, 2022

      Multiple Sclerosis, Relapsing-Remitting Trial in United States (Early Aggressive Therapy or Traditional Therapy)

      Recruiting
      • Multiple Sclerosis, Relapsing-Remitting
      • Early Aggressive Therapy or Traditional Therapy
      • Birmingham, Alabama
      • +51 more
      Jan 23, 2023